Clinical trialPhase 2Completed
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 16 November 2020
- Expected end
- 19 May 2023
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria
- Sponsor
- Other
- Results posted
- 2024-02-20
- Last update
- 23 February 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria [10 months]. Count Of Participants, Participants. Cemiplimab and Plerixafor (n=21): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Response Rate (ORR) Using RECIST 1.1 Criteria [10 months]. Count Of Participants, Participants. Cemiplimab and Plerixafor (n=21): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities [13 months]. Count Of Participants, Participants. Cemiplimab and Plerixafor (n=21): 4.